Expression of Tryptophan 2,3-Dioxygenase and Production of Kynurenine Pathway Metabolites in Triple Transgenic Mice and Human Alzheimer's Disease Brain

To assess the role of the kynurenine pathway in the pathology of Alzheimer's disease (AD), the expression and localization of key components of the kynurenine pathway including the key regulatory enzyme tryptophan 2,3 dioxygenase (TDO), and the metabolites tryptophan, kynurenine, kynurenic acid, quinolinic acid and picolinic acid were assessed in different brain regions of triple transgenic AD mice. The expression and cell distribution of TDO and quinolinic acid, and their co-localization with neurofibrillary tangles and senile β amyloid deposition were also determined in hippocampal sections from human AD brains. The expression of TDO mRNA was significantly increased in the cerebellum of AD mouse brain. Immunohistochemistry demonstrated that the density of TDO immuno-positive cells was significantly higher in the AD mice. The production of the excitotoxin quinolinic acid strongly increased in the hippocampus in a progressive and age-dependent manner in AD mice. Significantly higher TDO and indoleamine 2,3 dioxygenase 1 immunoreactivity was observed in the hippocampus of AD patients. Furthermore, TDO co-localizes with quinolinic acid, neurofibrillary tangles-tau and amyloid deposits in the hippocampus of AD. These results show that the kynurenine pathway is over-activated in AD mice. This is the first report demonstrating that TDO is highly expressed in the brains of AD mice and in AD patients, suggesting that TDO-mediated activation of the kynurenine pathway could be involved in neurofibrillary tangles formation and associated with senile plaque. Our study adds to the evidence that the kynurenine pathway may play important roles in the neurodegenerative processes of AD.

[1]  B. Brew,et al.  Quinolinic acid in the pathogenesis of Alzheimer's disease. , 2003, Advances in experimental medicine and biology.

[2]  D. Keskin,et al.  Indoleamine 2,3-dioxygenase, immunosuppression and pregnancy. , 2002, Journal of reproductive immunology.

[3]  D. Fuchs,et al.  Tryptophan degradation and immune activation in Alzheimer's disease , 2000, Journal of Neural Transmission.

[4]  George Perry,et al.  Indoleamine 2,3-dioxygenase and 3-hydroxykynurenine modifications are found in the neuropathology of Alzheimer's disease , 2010, Redox report : communications in free radical research.

[5]  O. Brown,et al.  Tryptophan metabolism through the kynurenine pathway in rat brain and liver slices. , 2000, Free radical biology & medicine.

[6]  O. Takikawa,et al.  Mechanism of interferon-gamma action. Characterization of indoleamine 2,3-dioxygenase in cultured human cells induced by interferon-gamma and evaluation of the enzyme-mediated tryptophan degradation in its anticellular activity. , 1988, The Journal of biological chemistry.

[7]  P. Mcgeer,et al.  Local neuroinflammation and the progression of Alzheimer’s disease , 2011, Journal of NeuroVirology.

[8]  B. Brew,et al.  Mass spectrometric detection of quinolinic acid in microdissected Alzheimer's disease plaques , 2007 .

[9]  Gilles J. Guillemin,et al.  The Excitotoxin Quinolinic Acid Induces Tau Phosphorylation in Human Neurons , 2009, PloS one.

[10]  B. Brew,et al.  Expression of the kynurenine pathway enzymes in human microglia and macrophages. , 2003, Advances in experimental medicine and biology.

[11]  N. Braidy,et al.  Effects of Kynurenine Pathway Inhibition on NAD+ Metabolism and Cell Viability in Human Primary Astrocytes and Neurons , 2011, International journal of tryptophan research : IJTR.

[12]  R. Beninger,et al.  Quinolinate-induced cortical cholinergic damage: modulation by tryptophan metabolites , 1990, Brain Research.

[13]  C. Colton,et al.  Activated human microglia produce the excitotoxin quinolinic acid , 1997, Neuroreport.

[14]  R. Schwarcz,et al.  Kynurenine 3-Monooxygenase Inhibition in Blood Ameliorates Neurodegeneration , 2011, Cell.

[15]  B. Brew,et al.  Characterization of the kynurenine pathway in human oligodendrocytes , 2007 .

[16]  G. Oxenkrug,et al.  Intensification of the central serotoninergic processes as a possible determinant of the thymoleptic effect. , 1969, Lancet.

[17]  F. Hirata,et al.  Indoleamine 2,3-dioxygenase. Purification and some properties. , 1978, The Journal of biological chemistry.

[18]  R. Rubin Adrenal cortical activity changes in manic-depressive illness. Influence on intermediary metabolism of tryptophan. , 1967, Archives of general psychiatry.

[19]  S. Weis,et al.  Upregulation of the initiating step of the kynurenine pathway in postmortem anterior cingulate cortex from individuals with schizophrenia and bipolar disorder , 2006, Brain Research.

[20]  G. Guillemin,et al.  Proinflammatory cytokine interferon‐γ increases induction of indoleamine 2,3‐dioxygenase in monocytic cells primed with amyloid β peptide 1–42: implications for the pathogenesis of Alzheimer’s disease , 2009, Journal of neurochemistry.

[21]  R. Yolken,et al.  Expression of the kynurenine pathway enzyme tryptophan 2,3-dioxygenase is increased in the frontal cortex of individuals with schizophrenia , 2004, Neurobiology of Disease.

[22]  P. Ricciardi-Castagnoli,et al.  Regulation of the Kynurenine Metabolic Pathway by Interferon‐γ in Murine Cloned Macrophages and Microglial Cells , 1996, Journal of neurochemistry.

[23]  D. Kranz,et al.  Neuronal localization of indoleamine 2,3-dioxygenase in mice , 2005, Neuroscience Letters.

[24]  M. Mattson,et al.  Triple-Transgenic Model of Alzheimer's Disease with Plaques and Tangles Intracellular Aβ and Synaptic Dysfunction , 2003, Neuron.

[25]  D. Nutt,et al.  Tryptophan metabolism in the central nervous system: medical implications , 2006, Expert Reviews in Molecular Medicine.

[26]  Gilles J Guillemin,et al.  Characterization of the Kynurenine Pathway in Human Neurons , 2007, The Journal of Neuroscience.

[27]  R. Pellicciari,et al.  Highlights at the gate of tryptophan catabolism: a review on the mechanisms of activation and regulation of indoleamine 2,3-dioxygenase (IDO), a novel target in cancer disease , 2009, Amino Acids.

[28]  G. Melillo,et al.  The Tryptophan Catabolite Picolinic Acid Selectively Induces the Chemokines Macrophage Inflammatory Protein-1α and -1β in Macrophages1 , 2000, The Journal of Immunology.

[29]  O. Takikawa Biochemical and medical aspects of the indoleamine 2,3-dioxygenase-initiated L-tryptophan metabolism. , 2005, Biochemical and biophysical research communications.

[30]  D. Munn,et al.  Inhibition of  T Cell Proliferation by Macrophage Tryptophan Catabolism , 1999, The Journal of experimental medicine.

[31]  Cheng-Hsien Lu,et al.  Elevated basal cortisol level predicts lower hippocampal volume and cognitive decline in Alzheimer’s disease , 2009, Journal of Clinical Neuroscience.

[32]  S. Mizuno,et al.  Tryptophan 2,3-dioxygenase is a key modulator of physiological neurogenesis and anxiety-related behavior in mice , 2009, Molecular Brain.

[33]  Identification and expression of alpha cDNA encoding human 2-amino-3-carboxymuconate-6-semialdehyde decarboxylase (ACMSD): a key enzyme for the tryptophan-niacine pathway and quinolinate hypothesis. , 2002, Advances in experimental medicine and biology.

[34]  B. Brew,et al.  Expression of indoleamine 2,3‐dioxygenase and production of quinolinic acid by human microglia, astrocytes, and neurons , 2005, Glia.

[35]  T. Stone,et al.  Quinolinic acid: a potent endogenous excitant at amino acid receptors in CNS. , 1981, European journal of pharmacology.

[36]  E. Major,et al.  Different kynurenine pathway enzymes limit quinolinic acid formation by various human cell types. , 1997, The Biochemical journal.

[37]  H. Rammensee,et al.  Levo- but not dextro-1-methyl tryptophan abrogates the IDO activity of human dendritic cells. , 2008, Blood.

[38]  R. Beninger,et al.  Picolinic acid modulates kainic acid-evoked glutamate release from the striatum in vitro , 1993, Brain Research.

[39]  S. Mandel,et al.  Gene expression analysis in N‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine mice model of Parkinson's disease using cDNA microarray: effect of R‐apomorphine , 2001, Journal of neurochemistry.

[40]  G. Guillemin Quinolinic acid, the inescapable neurotoxin , 2012, The FEBS journal.

[41]  G. Melillo,et al.  Immunobiology of picolinic acid. , 1996, Advances in experimental medicine and biology.

[42]  Toshikazu Nakamura,et al.  Identification and characterization of novel variants of the tryptophan 2,3-dioxygenase gene: Differential regulation in the mouse nervous system during development , 2009, Neuroscience Research.

[43]  C. Uyttenhove,et al.  Reversal of tumoral immune resistance by inhibition of tryptophan 2,3-dioxygenase , 2012, Proceedings of the National Academy of Sciences.

[44]  G. Melillo,et al.  The tryptophan catabolite picolinic acid selectively induces the chemokines macrophage inflammatory protein-1 alpha and -1 beta in macrophages. , 2000, Journal of immunology.

[45]  Y. Huang,et al.  Peripheral lipopolysaccharide (LPS) challenge promotes microglial hyperactivity in aged mice that is associated with exaggerated induction of both pro-inflammatory IL-1β and anti-inflammatory IL-10 cytokines , 2009, Brain, Behavior, and Immunity.

[46]  G. Oxenkrug Interferon-gamma-inducible kynurenines/pteridines inflammation cascade: implications for aging and aging-associated psychiatric and medical disorders , 2010, Journal of Neural Transmission.

[47]  Y. Egashira,et al.  Identification and expression of alpha cDNA encoding human 2-amino-3-carboxymuconate-6-semialdehyde decarboxylase (ACMSD): a key enzyme for the tryptophan-niacine pathway and quinolinate hypothesis. , 2002, Advances in experimental medicine and biology.

[48]  B. Brew,et al.  Kynurenine pathway metabolism in human astrocytes: a paradox for neuronal protection , 2001, Journal of neurochemistry.

[49]  O. Hayaishi,et al.  The oxygenated form of L-tryptophan 2,3-dioxygenase as reaction intermediate. , 1970, The Journal of biological chemistry.

[50]  B. Brew,et al.  Indoleamine 2,3 dioxygenase and quinolinic acid Immunoreactivity in Alzheimer's disease hippocampus , 2005, Neuropathology and applied neurobiology.